🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the fight against superbug strains of the infection, according to scientists.

An International Health Concern

Gonorrhoea infections are on the rise around the world, with figures suggesting more than 82 million new cases per year. Especially elevated rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Public health authorities are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "priority pathogen". Ongoing monitoring found that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Gain Authorization

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in recent days for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts believe that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, was also approved in concurrent days. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This approval represents a huge turning point in the treatment of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Outcomes and Worldwide Availability

Based on data released by a major medical journal, zoliflodacin successfully treated over nine in ten of cases of the STI. This puts it on an comparable level with the current standard treatment, which involves an injection and a pill. The trial included over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have expressed optimism. Having a one-pill regimen of this kind is hailed as a "critical tool" for gonorrhoea control. This is viewed as vital to lessen the impact of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea around the world.